Rosetta Genomics Secures Reimbursement Pricing, Shares Surge 15%

Shares of molecular diagnostic testing company Rosetta Genomics

are seeing increased strength during Tuesday's trading session after the company announced it secured Medicare reimbursement pricing. Rosetta Genomics said that the designated Medicare Administrative Contractor for its miRview® mets² assay has determined the assay to be reasonable and necessary for the diagnosis of cancers of unknown origin in a specified setting and has established a reimbursement rate for the assay. The miRview mets2 assay accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary. Currently, shares of Rosetta Genomics are trading up over 14% at $16.40 per share.